Symptoms and quality of life during immunotherapy for metastatic cancer
Official title: Symptomatic Toxicities & Quality of Life among Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer.
Funded at University of Miami School of Medicine · NIH-11267220 · Data updated 2026-11-12
The team will track symptoms and day-to-day quality of life in people with metastatic cancer who are receiving immune checkpoint inhibitor treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $985,114 |
| NIH project number | 5R37CA288566-02 |
| Project ID | NIH-11267220 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic solid tumors who are starting or currently receiving immune checkpoint inhibitor therapy would be the ideal candidates.
✕Less likely to help
People who are not receiving immune checkpoint inhibitors, those with non-metastatic disease, or those unable to complete regular patient-reported questionnaires may not benefit directly from this project.
What this research studies
If you join, you'll be asked to report symptoms and quality-of-life information while you receive immune checkpoint inhibitor therapy for metastatic cancer. The researchers will collect patient-reported outcome questionnaires over time and link those reports to clinical records about side effects, hospital visits, and treatment details. They will look for when symptoms start, which patients develop severe or late side effects, and how these problems affect daily life. The findings are meant to help doctors better manage immunotherapy side effects and support patients during and after treatment.
Why it matters
Potential benefit: If successful, this work could improve how clinicians spot and manage immunotherapy side effects, helping to protect quality of life for people on these treatments.
How similar studies have gone: Some previous studies have collected patient-reported symptoms during immunotherapy, but long-term, detailed linking of symptoms to clinical outcomes remains limited so this approach is still emerging.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Moreno, Patricia Ingrid — University of Miami School of Medicine
- Study coordinator: Moreno, Patricia Ingrid
Related research
Other NIH-funded projects on the same topics.
-
Understanding side effects and quality of life for diverse patients using immune therapies for cancer.
This study is looking at how different people with advanced cancer feel while getting immune checkpoint inhibitors, focusing on their side effects and quality of life, to help improve support and care for patients like you.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples
A study in people with non-small cell lung cancer will look at blood and tumor samples to understand why some patients benefit from immunotherapy and who might have serious side effects.
-
Understanding skin reactions from immune cancer drugs and how our body’s immune system reacts to them
This grant explores why some people develop severe skin reactions when treated with immune checkpoint inhibitors and aims to use patient data and tissue studies to improve care.
-
Targeting NNMT in the tumor environment to make immunotherapy work better
Aiming to boost cancer treatment by blocking NNMT in the tumor’s supportive tissue so immune therapies work more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.